The Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) published a call for project proposals on Development of therapeutics and diagnostics combatting coronavirus (COVID-19) infections. The deadline to submit project proposals is 31 March 2020.
The purpose of this call is to gain a better understanding of the newly identified coronavirus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients' health and contain the spread of COVID-19.
Considering that this is a newly identified virus, the scope of this topic remains broad and must address one of the following objectives:
- Development of antiviral drugs and other therapeutics to address a rapid response towards the current COVID-19 outbreak;
- Development of therapeutics to address the current and/or future coronaviruses outbreaks;
- Development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies;
- Development of fast and reliable detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.
This call is open to public entities, micro, small and medium-sized enterprises, academia, non-profit organisations, and international European organisations.
The budget for the call is EUR 45 000 000.
Details about the Call are available at https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/imi2-2020-21-01.
The Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The IMI2 JU objectives are implemented through Research and Innovation Actions (RIAs), and Coordination and Support Actions (CSAs) where public and private partners collaborate, joining their expertise, knowledge and resources.